Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Caplin Point Laboratories Ltd

CAPLIPOINT.NS ✓ COMPLIANT ☆ Track — members

NSE India · Healthcare · Pharmaceuticals ·

India Small Cap Analyst: STRONG BUY

Last Close

$25.99

▼ -0.77%

Market Cap $1.98B · Vol 56.75K

Key Metrics

P/E Ratio

28.42

FWD: 25.15

Market Cap

$1.98B

Small Cap

Div Yield

0.32%

Semi-annual dividend

EPS Growth

+10.85%

YoY

RSI (14)

37.29

Momentum

Beta

1.13

vs Market

52W High

$28.28

8.03% below

52W Low

$15.72

63.45% above

Volume

56.75K

Avg 112.64K

P/B

3.19

Price-to-book

ROE

19.92%

Return on equity

Free Float

26.39%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Caplin Point Laboratories Ltd (CAPLIPOINT.NS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CAPLIPOINT.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.64%

-6.69%

+22.57%

+43.28%

YTD

+34.95%

+16.17%

+112.96%

+191.63%

Financials & Valuation

TTM · Annual

Total Revenue	$234.03M
Net Income	$69.52M
Revenue Growth (YoY)	+19.63%
Gross Margin	57.09%
Operating Margin	31.46%
Net Profit Margin	29.71%
ROE	19.92%
ROA · ROIC	22.14% · 19.64%

P/E Ratio	28.42
Forward P/E (FY1)	25.15
PEG Ratio	0.91
P/S	5.25
P/B	3.19
P/FCF	34.08
EPS Growth	+10.85%
Outstanding Shares	76.01M

Technical Indicators

50-Day SMA	$26.30
200-Day SMA	$20.92
RSI (14)	37.29
Beta	1.13
52-Week High	$28.28
52-Week Low	$15.72

Volume Today	56.75K
Avg Daily Volume (30D)	112.64K
Relative Volume	0.50x
Volatility (10D)	35.93
Volatility (30D)	38.05
Free Float	26.39%

Analyst Consensus

STRONG BUY

Current Price $25.99

Mean Target $26.00

52W Low$15.72 52W High$28.28

Current

Target

$15.72 $28.28

Current Analyst target

+0.04% upside potential · 3 analysts

Identifiers

ExchangeNSE India

FIGIBBG001S8G5V6

ISININE475E01026

CountryIndia

Sub-IndustryGeneric Pharmaceuticals

Earnings DateNov 6, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

SUNPHARMA.NS Sun Pharmaceutical Industries Ltd -0.10% 4578.T Otsuka Holdings Co Ltd -3.26% CIPLA.NS Cipla Ltd -0.60% ZYDUSLIFE.NS Zydus Lifesciences Ltd -2.75% RICHTER.BU Richter Gedeon Vegyeszeti Gyar Nyrt +1.56%

Company Profile

Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.